Get started
Author

Pablo M. Aviles

Observed names: Pablo Aviles, Pablo Avilés
Institution: PharmaMar (Spain)
Observed institution: PharmaMar (Spain)
ORCID: 0000-0001-7922-6042
Observed ORCID: 0000-0001-7922-6042
OpenAlex ID: A5108298552
Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung Cancer
2024 · Antonio Calles, Emiliano Calvo, et al. · Molecular Cancer Therapeutics · 14
Validation of a sensitive assay for thiocoraline in mouse plasma using liquid chromatography–tandem mass spectrometry
2003 · Jianming Yin, Pablo Aviles, et al. · Journal of Chromatography B · 11
Plitidepsin as an Immunomodulator against Respiratory Viral Infections
2024 · Alejandro Losada, Nuria Izquierdo-Useros, et al. · The Journal of Immunology · 7
PDF
PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity
2025 · Pablo Aviles, Marcelo Lima Ribeiro, et al. · Molecular Cancer Therapeutics · 4
PDF
The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al. · Cancer Research · 3
Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor
2025 · Jose Jimeno, Jose Felipe Varona, et al. · Molecular Aspects of Medicine · 3
Investigating the role of G-quadruplex-associated duplex stem loops in Trabectedin’s mechanism of action
2026 · Alena Safarova, Raquel Altares, et al. · Scientific Reports · 1
PDF
Data from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Table 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S3 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Table 5 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Methods from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Table 4 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S6 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S7 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S4 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S5 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Table 3 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Table 2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplemental Figure 5 from Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts
2026 · Daniël Gorgels, Chao-Chi Wang, et al.
Supplemental Table 2 from Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts
2026 · Daniël Gorgels, Chao-Chi Wang, et al.
Supplemental Figure 1 from Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts
2026 · Daniël Gorgels, Chao-Chi Wang, et al.
Supplemental Figure 2 from Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts
2026 · Daniël Gorgels, Chao-Chi Wang, et al.
Works count: 58
Citation count: 43
H-index: 4
I10-index: 2
Year
Topic
Type